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0163-7258/© 2016 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oAvailable online 29 June 2016 Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that constitutes a major global
health burden. A signiﬁcant proportion of patients experience skeletal muscle wasting and loss of strength as a
comorbidity of their COPD, a condition that severely impacts on their quality of life and survival. At present,
the lung pathology is considered to be largely irreversible; however, the inherent adaptability of muscle tissue
offers therapeutic opportunities to tackle muscle wasting and potentially reverse or delay the progression of
this aspect of the disease, to improve patients' quality of life. Muscle wasting in COPD is complex, with contribu-
tions from a number of factors including inﬂammatory cytokines, oxidative stress, growth and anabolic hor-
mones, nutritional status, and physical activity. In this review, we discuss current and emerging therapeutic
approaches to treat muscle wasting in COPD, including a number of pharmacological therapies that are in devel-
opment for muscle atrophy in other pathological states that could be of relevance for treating muscle wasting in
COPD patients.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
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Wasting1. Introduction—Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a progressive lung
disease caused by excessive inﬂammation leading to irreversible dam-
age to the airways and lung tissue. Symptoms include cough and short-
ness of breath, relating to underlying small airways disease with or
without chronic bronchitis, and emphysema (an enlargement of the air-
spaces caused by destruction of the alveoli). COPD is a major global
health burden and is currently the 3rd leading cause of deathworldwide
(Lozano et al., 2012). A major cause of COPD is cigarette smoking;disease; GOLD, Global Initiative
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. This is an open access article underhowever, COPD may also occur in non-smokers. Other important risk
factors for COPD include inhalation of noxious substances such as partic-
ulatematter inwood smoke, air pollution or dust (Salvi & Barnes, 2009),
asthma, and genetic factors. The severity of airﬂow limitation in COPD is
graded based on spirometric measurements of lung function according
to the Global Initiative for Chronic Obstructive Lung Disease (GOLD)
criteria, with the mildest airﬂow limitation classed as GOLD 1,
progressing to the most severe airﬂow limitation at GOLD 4 (GOLD,
2016). COPD is increasingly being recognized as a systemic disease,
and additional metrics such as body mass index (BMI), degree of short-
ness of breath (dyspnea), and physical capacity (6-minute walk dis-
tance, 6MWD) are also predictive of patient outcomes (Celli et al.,
2015).
The pulmonary pathology of COPD arises due to remodeling and
narrowing of the airways, and damage to the lung parenchyma that
leads to alveolar damage and emphysema (Barnes, 2014). Development
and progression of the disease is driven by chronic inﬂammation and
oxidative stress within the lungs, initiated in response to inhalation of
noxious substances. Inﬂammation is perpetuated by immune cells
such as neutrophils and macrophages recruited to the lungs as part of
the inﬂammatory response. Once the process is initiated, the disease
progresses due to persistent inﬂammation and the production ofthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ternal stimuli such as cigarette smoke.
In addition to chronic inﬂammation and oxidative stress in stable
COPD, patients are also more susceptible to respiratory infections,
which are the predominant cause of acute exacerbations of COPD
(AECOPD). During an exacerbation, patients experience a worsening
of their symptoms, including increased sputum production and dys-
pnea, necessitating a change to their regular medication and often re-
quiring hospitalization for additional treatment. Acute exacerbations
can accelerate the decline in lung function in COPD patients, through
the generation of persistent inﬂammation within the lungs (Wedzicha
et al., 2014).
The pathology of COPD extends beyond the lung environment, giv-
ing rise to systemic effects and the development of a number of comor-
bidities including skeletal muscle wasting, cardiovascular disease, and
osteoporosis (Barnes & Celli, 2009).
2. Skeletalmuscle wasting in chronic obstructive pulmonary disease
Skeletalmusclewasting and dysfunction is experienced by up to 40%
of COPD patients (Schols et al., 2005; Sergi et al., 2006; Vestbo et al.,
2006) and loss of muscle mass is commonly assessed by measuring
the patients' fat-free mass index (FFMI). Some studies have shown
that the incidence of patients with a low FFMI increaseswith disease se-
verity, reaching 50% in patients with GOLD stage 4 COPD (Vestbo et al.,
2006), reﬂecting an association between muscle mass and the severity
of the lung pathology. Muscle dysfunction is, however, observed
across the full spectrum of COPD severities—an important observation
suggesting thatmuscle is affected from an early stage in the progression
of COPD and could be effectively targeted therapeutically before it be-
comes a debilitating condition.
COPD develops slowly but inexorably with most COPD patients
being diagnosed at age 45 or older. While it is normal for people to ex-
perience a decline inmusclemasswith increasing age, COPD patients in
one study experienced a decline in muscle mass of up to 4.3% per year
(Hopkinson et al., 2007), approximately double the rate of decline asso-
ciated with ageing (Frontera et al., 2000). The clinical impact of muscle
wasting in COPDpatients is signiﬁcant, resulting in not only reduction in
quality of life, independence, and exercise capacity, but also overall sur-
vival. Patients with severe COPD who have reduced mid-thigh cross-
sectional area (less than 70cm2) have an approximately 4 times higher
odds ratio for mortality than similar patients with a similar degree of
airﬂow limitation but with preserved muscle size (Marquis et al.,
2002). Low FFMI and reduced quadriceps strength have been identiﬁed
as predictors of COPD mortality, independent of lung function decline
(Schols et al., 2005; Swallow et al., 2007), highlighting the importance
of muscle mass and function in the overall pathology of COPD.
Concomitant with a reduction in muscle mass is a loss of strength in
the limbmuscles. Interestingly, it appears that the lower limbs aremore
susceptible towasting than the upper limbmuscles (Caron et al., 2009),
a feature that is similar to the pattern of wasting seen in disuse. While
this suggests that disuse plays a signiﬁcant role in wasting in COPD, it
is likely that other mechanisms also contribute and therapies could be
combined with exercise training to yield overall improvements in mus-
cle strength and function.
The maximum voluntary contraction of the quadriceps muscles is
reduced by as much as 40% in COPD patients (Bernard et al., 1998;
Plant et al., 2010; Seymour et al., 2010). Some studies have demonstrat-
ed an increase in the prevalence of quadriceps weakness with increas-
ing COPD severity (Kharbanda et al., 2015) and a positive correlation
between mid-thigh cross-sectional area and severity of airﬂow limita-
tion (Bernard et al., 1998), indicating a link between the severity of
the lung pathology and the extent of muscle impairment. However,
signiﬁcant muscle weakness has also been detected in patients with
mild COPD (GOLD stages 1–2) or mild dyspnea (Seymour et al., 2010)
and even in smokers without COPD compared to healthy controls(Seymour et al., 2010; Kok et al., 2012), suggesting that skeletal muscle
dysfunctionmay occur at an early stage even prior to the onset of respi-
ratory symptoms.
In addition to loss of muscle mass and strength, phenotypic changes
also occur in the muscle of COPD patients. A shift in the ﬁber types has
been observed, with an increase in the proportion of fast glycolytic
Type II ﬁbers and a reduction in slow, oxidative Type I ﬁbers (Jobin
et al., 1998; Whittom et al., 1998; Debigare et al., 2003; Gosker et al.,
2007; Vogiatzis et al., 2011).
Skeletalmusclemass is adversely affected both during and following
an acute exacerbation; quadriceps strength declines in hospitalized pa-
tients during an AECOPD and only partially recovers even up to 90 days
following an exacerbation in the absence of interventions such as pul-
monary rehabilitation (Spruit et al., 2003).More frequent exacerbations
are associatedwith amore rapid decline in strength (Ansari et al., 2012),
further suggesting a link between AECOPD and muscle health.
Weight loss andweakness have long been observed in patients with
COPD, but it is only in recent decades that we have begun to understand
at the molecular level the processes contributing to wasting. To date,
therapeutic options to restore muscle mass have been limited. In
2006, we reviewed the development of therapies for muscle wasting
in COPD (Hansen et al., 2006). Hereweprovide anupdate on the current
state of therapy targeting COPD-associated muscle dysfunction,
discussing some of themechanisms ofmusclewasting aswell as the ad-
vancement of therapeutic options in the last decade. We also discuss
emerging therapies in development and clinical trials to treat muscle
wasting in other conditions such as cancer cachexia and sarcopenia
that share some similarities with the wasting observed in COPD, as
these may be of relevance for the treatment of COPD patients to restore
muscle mass and function.
3. Pathways regulating skeletal muscle mass
Broadly speaking, overall muscle mass is regulated by the balance
between protein synthesis and protein degradation, with additional
contributions from regenerative processes and satellite cells. In cases
of atrophy in response to disuse, immobilization, or pathological condi-
tions such as cancer cachexia, the balance shifts toward an increase in
protein degradation and a decrease in protein synthesis. The overall
aim in developing therapeutic approaches to tackle muscle wasting is
to push the balance in the opposite direction, increasing protein synthe-
sis and decreasing protein breakdown to lead to an overall increase in
muscle mass.
Themechanisms and signaling pathways regulatingmuscle anabolic
and catabolic processes are complex (Fig. 1). These intracellular
pathways are controlled by a wide range of extracellular factors
including inﬂammatory mediators, oxidative stress, circulating hor-
mones, nutritional and exercise factors. In addition, chronic use of
anti-inﬂammatory corticosteroids such as prednisolone is known to
cause muscle weakness and atrophy, through their effects on various
signaling pathways regulating muscle mass (Decramer et al., 1994).
The major pathway leading to muscle growth (hypertrophy) is
through the insulin-like growth factor (IGF-1)/Akt/mTOR pathway,
which promotes protein synthesis through stimulation of protein trans-
lation via activation of positive regulators of translation (p70S6 kinase)
and inhibition of the negative regulator 4E-BP1 (Glass, 2003). Akt sig-
naling also inhibits the FoxO transcription factors, leading to inhibition
of the ubiquitin proteasomepathway and decreasingmuscle proteolysis
(Stitt et al., 2004). Muscle mass can also be increased through regener-
ative pathways following the activation of the muscle-resident stem
cells, called satellite cells (Charge & Rudnicki, 2004).
Opposing the hypertrophy pathway are mechanisms that lead to at-
rophy. Muscle atrophy is largely driven by increased proteolytic break-
down ofmuscle proteins via the ubiquitin–proteasome system. Proteins
are targeted for degradation by the proteasome by the covalent attach-
ment of multiple ubiquitin molecules by ubiquitin-ligase proteins. A
Fig. 1.Overview of signaling pathways regulating atrophy and hypertrophy of skeletalmuscle. ROS, reactive oxygen species;MAPK,mitogen-activated protein kinase; NFκB, nuclear factor
kappa B; FoxO, forkhead box; IGF-1, insulin-like growth factor 1; Akt, protein kinase B; mTOR, mammalian target of rapamycin; AR, androgen receptor.
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muscle, including atrogin-1/Fbxo32 and muscle ring ﬁnger 1 (MuRF-
1/Trim63), and expression of these proteins is often elevated in condi-
tions of muscle atrophy (Bodine et al., 2001; Gomes et al., 2001;
Bodine & Baehr, 2014; Yuan et al., 2015), reﬂecting the central role of
the proteasome in regulating protein catabolism in atrophic states. An
additional pathway of protein breakdown is the autophagy pathway
that is responsible for degradation of organelles and other cellular con-
stituents through the lysosomal degradation process (Hussain & Sandri,
2013).
Alterations in many of these pathways have been characterized in
the muscle of COPD patients and are associated with loss of muscle
mass in these patients. Increased expression of atrogenes – genes that
encode proteins involved in muscle atrophy pathways – has been mea-
sured in COPD. Themuscle-speciﬁc E3 ligases atrogin-1 andMuRF-1 are
upregulated in COPD muscles (Doucet et al., 2007; Plant et al., 2010),
suggesting an upregulation of the Ub-proteasome system and increased
proteolysis. Indeed, increased muscle protein breakdown occurs in ca-
chectic COPD patients compared to COPD patients with normal FFM
and healthy controls (Rutten et al., 2006). There is little information
on the contribution of the autophagy pathway to muscle protein break-
down; however, Plant et al. detected no change in the levels of autoph-
agy proteins beclin-1 and LC3, suggesting that autophagy was not
upregulated in the muscle from COPD patients in that cohort (Plant
et al., 2010).
While reduced IGF-1 expression has been observed in some COPD
patients (Plant et al., 2010), consistent with a decrease in protein syn-
thesis, others have reported upregulated phosphorylated Akt and
other components of the Akt/mTOR pathway in muscle from COPD pa-
tients (Doucet et al., 2007). It has been suggested that in the presence of
strong atrophy signaling, the Akt pathway, may be upregulated in an ef-
fort to normalizemusclemass (Doucet et al., 2007); however, themech-
anisms underlying these ﬁndings are yet to be fully explored.
Satellite cells in the muscle of COPD patients show evidence of se-
nescence (Theriault et al., 2012), and COPD patients exhibit reduced
muscle regenerative capacity (Theriault et al., 2014). Isolated satellite
cells from COPD patients show reduced myotube diameter and in-
creased atrophy signaling and oxidative stress in vitro (Pomies et al.,
2015), suggesting an inherent alteration in the satellite cells themselves
could be contributing to the reduced regenerative ability in COPDpatients. The exact role of satellite cells and their ability to contribute
to muscle regeneration in COPD is not yet fully understood and further
investigation into this area is needed.
4. Inﬂammation
The link between inﬂammation and skeletal muscle health is well
established. A number of inﬂammatory cytokines, including tumor ne-
crosis factor (TNF)-α and interleukin (IL)-6, are known to induce mus-
cle atrophy in animalmodels and healthy human volunteers (Goodman,
1991, 1994; Haddad et al., 2005; Bach et al., 2013; Zhou et al., 2016).
Pro-inﬂammatory mediators including TNF-α, IL-6 and C-reactive pro-
tein (CRP) are elevated in COPD patients (Yende et al., 2006; Vogiatzis
et al., 2007) and are associated with reduced muscle function. Elevated
IL-6 levels have been associated with reduced lung function and in-
creased muscle wasting in COPD patients compared to healthy elderly
controls (Yende et al., 2006).
TNF-α is a key cytokine in the regulation of muscle mass signaling
via a number of pathways to reducemuscle protein content and satellite
cell differentiation. Through activation of the transcription factor NF-κB,
TNF-α induces expression of MuRF-1 and increases activity of the ubiq-
uitin–proteasome pathway leading to muscle protein degradation
(Llovera et al., 1997). TNF-α-induced activation of the p38 mitogen-
activated protein kinase (MAPK) pathway stimulates expression of
atrogin-1 (Li et al., 2005), and this is proposed to be through the tran-
scription factor FoxO4 (Moylan et al., 2008). In addition, TNF-α reduces
muscle regeneration via inhibition of the myogenic regulatory factor
MyoD (Guttridge et al., 2000; Langen et al., 2001). Given the established
effects of TNF-α in muscle atrophy, and the association between elevat-
ed TNF-α levels and reducedmuscle strength in COPD, targeting this cy-
tokine therapeutically is an attractive prospect. This notion is supported
by evidence frommouse cancermodels, where inhibiting TNF-α signal-
ing through administration of a soluble TNF-α receptor resulted in both
increased bodyweight and increased appetite in tumor-bearing mice
(Torelli et al., 1999).
Despite the important role of TNF-α in mediating muscle wasting
and encouraging preclinical data supporting the use of anti-TNF-α
agents for muscle wasting, the results of clinical trials for both muscle
wasting in a range of conditions and the lung pathology of COPD have
been somewhat disappointing (See Table 1). Treatment with the anti-
Table 1
Pharmaceutical therapies targeting chronic inﬂammation and oxidative stress for treatment of muscle wasting.
Drug name Mode of action Application Results Reference
Anti-cytokine
Etanercept (Enbrel) Anti-TNFα fusion protein Cancer cachexia No improvement in bodyweight Jatoi et al., 2007
Inﬂiximab (Remicade) Anti-TNFαmonoclonal antibody Cancer cachexia No improvement in bodyweight, increased
fatigue and reduced quality of life
Jatoi et al., 2010
ALD518 (Alder Biopharmaceuticals) Anti-IL-6 Cancer cachexia Reduction in patients losing N5% bodyweight
Reduced fatigue
Bayliss et al., 2011
Tocilizumab IL-6 receptor antibody Cancer cachexia Improved bodyweight and appetite (case study) Ando et al., 2013
MABp1 (Xilonix, Xbiotech) Anti-IL-1α antibody Cancer cachexia Increased lean body mass, reduced fat mass.
Reduced fatigue and increased quality of life scores
Hong et al., 2014
Dietary antioxidants
Vits C & E, α-lipoic acid ROS scavenger COPD No improvement in muscle time to exhaustion Rossman et al., 2013
Resveratrol Numerous: ROS scavenger, increases
antioxidant enzyme activity
COPD In progress NCT02245932
Thiols
NAC Cysteine donor/ROS scavenger COPD Improved endurance but no effect on fatigue
or dyspnea
Koechlin et al., 2004
59S.L. Passey et al. / Pharmacology & Therapeutics 166 (2016) 56–70TNF-α agent etanercept in cancer patients showed no signiﬁcant im-
provement in bodyweight compared to those treated with the placebo
(Jatoi et al., 2007). Similar results were seen in a later trial where pa-
tients were treated with the anti-TNF-α monoclonal antibody
inﬂiximab, and patients reported increased fatigue and an overall re-
duction in quality of life following inﬂiximab treatment (Jatoi et al.,
2010). In this study, no patients reached the primary endpoint of 10%
or greater weight gain, and the trial was terminated early due to the
lack of efﬁcacy (Jatoi et al., 2010). It isworthwhile noting thatwhile can-
cer cachexia and the wasting associated with COPD may be initiated by
differing pathological conditions, the underlyingmolecular changes and
mechanisms have been shown to be similar. For example, similar alter-
ations in levels of oxidative stress and systemic inﬂammation, signaling
pathways andmuscle architecture have been observed in themuscles of
patients with both lung cancer and COPD (Puig-Vilanova et al., 2015).
Therapies targeting cachexia in cancer may prove to be of value to
treat muscle wasting in COPD.
There has been considerable interest in targeting TNF-α in COPD as
preclinical studies using TNF knockoutmice display amarked reduction
in lung inﬂammation and emphysema in experimental cigarette smoke
models (Churg et al., 2004). However, a clinical study using anti-TNF
therapy (Inﬂiximab) failed to improve outcomes for COPD patients in-
cluding symptom score, lung function, exercise capacity, dyspnea
score, health status, and rate of acute exacerbations (Rennard et al.,
2007). Anti-TNF-α therapies have been similarly ineffective at reducing
local and systemic inﬂammation in COPD patients (Loza et al., 2012)
and to date have not resulted in any overall clinical beneﬁt in terms of
the lung pathology (van der Vaart et al., 2005; Rennard et al., 2007).
The reasons for this are unclear; however, there are important features
that contribute to the differential response to blocking the function of
TNF-α in preclinical experimental models versus human clinical trials.
It is well established that the cigarette smoke exposure mouse model
represents amild stage of COPDwhere there ismodest airspace enlarge-
ment and airway remodeling. In these models, therapies are either ap-
plied prophylactically to prevent development of disease or the gene
of interest is knocked out prior to exposure. This is in contrast to the
clinical scenario, where anti-TNF trials have been performed on COPD
patients with severe or very severe COPD.
Hence, therapies would need to reverse established disease patholo-
gy including muscle wasting in order for the patient to obtain beneﬁt
from the treatment. An alternative approach would be to perform clin-
ical trials on early-stage or mild COPD patients and determine whether
anti-TNF-α therapy prevents or slows progression of disease as seen in
experimental models; however, such an approach is cost prohibitive at
this stage and chronic administration of TNF-α blockers have been
linked to an increase risk of clinically diagnosed pneumonia and lungmalignancies (Rennard et al., 2007). It is increasingly recognized that
therapies will continue to fail in large COPD trials that include a broad
spectrum of clinical and molecular phenotypes, which fall within a de-
ﬁned group based on lung function. Novel therapies targeted toward
improving muscle function in advanced COPD patients should ﬁrst be
assessed for their ability to reverse established or severe disease in
novel preclinical models. A better approach would be to prevent pro-
gression of disease and muscle wasting, where preclinical models can
be informative; however, the application of long-term trials in early-
stage disease remains a challenging prospect for industry. Another im-
portant limitation of targeting TNF-α is the multifactorial and multi-
cytokine nature of COPD and skeletal muscle wasting; it is likely that
the inhibition of a single cytokine is not sufﬁcient to overcome the com-
plex wasting pathways and disease pathology and lead to detectable
clinical improvement.
While not currently used for treatment of muscle wasting in COPD,
anti-IL-6 therapies have shown promise in the treatment of cancer ca-
chexia. The humanized anti-IL-6 monoclonal antibody ALD518 has a
high afﬁnity for binding IL-6, and clinical trials in non-small-cell lung
cancer have yielded some positive results, including a signiﬁcant reduc-
tion in the proportion of patients losingmore than 5% lean bodymass as
well as improvements in overall scores of fatigue (Bayliss et al., 2011).
Tocilizumab, an IL-6 receptor antibody, has been reported to improve
cachexia in two patients (Ando et al., 2013) and also in amouse cachex-
ia model (Ando et al., 2014), but has yet to be tested on a larger scale in
human studies.
Similarly to other cytokines, signaling through the IL-1 receptor
stimulates muscle atrophy via upregulation of atrogene expression
and inhibition of IGF-1 signaling (Benbassat et al., 1999; Li et al.,
2009). Both IL-1β, and more recently, IL-1α, have been shown to be el-
evated in the lungs of COPD patients compared to never smokers
(Botelho et al., 2011; Pauwels et al., 2011), suggesting a role for these
cytokines in the pathology of COPD. Initial clinical trials of MABp1, a
monoclonal anti-IL-1α antibody, demonstrated an increase in lean
body mass in 70% of MABp1-treated cancer patients, along with im-
provements in fatigue and general quality of life scores (Hong et al.,
2014). Although the trialwas small with only 30 patients being assessed
for bodymass by dual energy X-ray absorptiometry (DEXA) scan, it is of
interest that the patients who experienced a gain in lean bodymass also
saw a reduction in fat mass, suggesting a role for IL-1α in regulation of
metabolism and body composition. Such an effect could be of beneﬁt
in COPD patients, where body composition is often altered such that pa-
tients display increased abdominal adiposity while simultaneously los-
ing muscle mass in their limbs (Schols et al., 2005).
During an exacerbation, inﬂammation is elevated above the levels
seen in stable COPD patients. In addition, the acute phase protein
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been identiﬁed as a biomarker for the severity of the exacerbation
(Bozinovski et al., 2008). We have recently shown that SAA has direct
effects on muscle cells, inducing both the expression of pro-
inﬂammatory cytokines and an atrophy response (Passey et al., 2016).
These ﬁndings suggest that acute phase proteins elevated in COPD or
during an exacerbation could be contributing to the decline in muscle
function observed during and following an exacerbation. The regulation
of SAA in the circulation is complex, and SAA is known to interact with a
number of cell surface receptors. As yet there are no therapeutics
targeting SAA-mediated inﬂammation in the clinic; however, ap-
proaches aimed at promoting the resolution of inﬂammation through
the administration of mediators that oppose the actions of SAA could
hold promise (Bozinovski et al., 2014).
5. Oxidative stress
Oxidative stress is emerging as an important contributor to both the
lung and systemic pathologies of COPD. Recent detailed reviews de-
scribe the mechanisms by which oxidative stress contributes to COPD
pathology in the lung (Rahman & Kinnula, 2012) and to the develop-
ment of systemic comorbidities (Bernardo et al., 2015), and readers
are directed to these extensive reviews for more detailed information
on this topic. Oxidative stress and damage occurs when there is an im-
balance between the levels of oxidants and antioxidants, leading to an
excess of highly reactive oxygen species (ROS) including superoxide,
hydroxyl radicals and hydrogen peroxide, and reactive nitrogen species
(RNS) such as nitric oxide and peroxynitrite (Bernardo et al., 2015). This
imbalance can arise due to reduced antioxidant defenses or increased
oxidant production.
In the context of COPD, there is a high oxidant burden within the
lungs arising both as a result of the oxidants found within cigarette
smoke and also due to endogenous oxidants produced by leukocytes re-
cruited to the lung as part of the inﬂammatory response (Rahman &
Kinnula, 2012). Oxidative stress is also acutely elevated following exer-
cise in COPD patients (Van Helvoort et al., 2006; Fisher-Wellman et al.,
2009; Mercken et al., 2009). In healthy populations, such acute in-
creases act as a stimulus for increased antioxidant defenses, resulting
in a lower overall oxidative stress over time. These responses appear
to be partially blunted in COPD patients with low muscle mass
(Fisher-Wellman et al., 2009).
There is an increased concentration of hydrogen peroxide (H2O2) in
exhaled breath condensate of COPD patients and this is further elevated
during AECOPD (Dekhuijzen et al., 1996; Nowak et al., 1996). Increased
levels of the oxidation product malondialdehyde (MDA) are present in
both the sputum and plasma of COPD patients (Zeng et al., 2013), and
increased lipid peroxidation and protein carbonylation has also been
measured in plasma from COPD patients compared to healthy controls
(Santos et al., 2004; Nadeem et al., 2005), indicating an increase in sys-
temic oxidative stress in COPD. The level of local lung oxidative stress
correlates with systemic (plasma) levels of oxidative stress (Zeng
et al., 2013), lending support to the ‘spillover’ hypothesis that oxidants
and inﬂammation within the lungs can extend into the systemic circu-
lation leading to the development of systemic comorbidities of COPD.
Antioxidant defenses including superoxide dismutase (SOD), gluta-
thione peroxidase (Gpx) and glutathione levels have been found to be
decreased in COPD and AECOPD patients compared to smokers and
healthy controls (Nadeemet al., 2005; Zeng et al., 2013), further indicat-
ing that an imbalance in antioxidant/oxidant status exists in patients
with COPD.
In addition to oxidative damage in the lungs and plasma, total pro-
tein carbonylation is elevated in the vastus lateralis muscle of COPD pa-
tients compared to healthy controls (Barreiro et al., 2008), and levels of
protein carbonylation correlate inversely with quadriceps strength
(Barreiro et al., 2010). MDA-protein adducts and tyrosine nitration is
also increased in muscle from COPD patients, and in cigarette smoke-exposed rodent models (Barreiro et al., 2010). A number of abundant
proteins with important functions in glycolysis, energy production and
muscle contraction show increased levels of carbonylation in both
COPD patients and in cigarette smoke-exposed guinea pigs compared
to controls (Barreiro et al., 2010). Interestingly, oxidative changes
have also been detected in muscle from non-COPD smokers and in ani-
mal models before the onset of overt lung pathology (Barreiro et al.,
2010), indicating that cigarette smoke itself can exert an oxidative bur-
den onmuscle that could contribute to the development of muscle dys-
function at early stages of COPD development.
The function of skeletal muscle is regulated in part by endogenous
ROS and RNS, which are involved in processes such as contractile func-
tion, glucose uptake, and regenerative processes (Espinosa et al., 2016).
ROS and RNS production increases during muscle contraction, and
hence muscle has a high level of endogenous antioxidant defenses to
prevent excess oxidative damage from free radicals generated during
exercise and daily movement. Endogenous antioxidant defenses are
often upregulated in the muscle of COPD patients (Gosker et al., 2005;
Barreiro et al., 2009; Rodriguez et al., 2012) and the clinical beneﬁt of
antioxidant therapies to ameliorate muscle dysfunction in COPD is not
yet clear. However, the elevated levels of oxidative damage observed
in the muscle of COPD patients and the link between oxidative stress
and muscle strength suggest that in the context of COPD, the levels of
oxidative stress overwhelm the endogenous defenses. Thus, therapy
aimed at reducing oxidative stress in muscle could be of beneﬁt for im-
proving the muscle pathology in COPD.
Therapeutic strategies to target oxidative stress include the use of
scavengingmolecules to ‘mop up’ excess oxidants and also the adminis-
tration of molecules that mimic or increase the activity of endogenous
antioxidant proteins such as SOD and Gpx.
5.1. Dietary antioxidants
Many antioxidant compounds are naturally occurring and can be ob-
tained fromdietary sources or through dietary supplementation, includ-
ing vitamins E and C, carotenes, and resveratrol. Clinical trials of dietary
antioxidants have yieldedmixed results. Oral administration of vitamins
E and C has been shown to be effective in reducingmarkers of oxidative
stress but does not improve measures of fatigue in healthy people
(Bentley et al., 2015) or COPDpatients (Rossman et al., 2013). A recently
completed trial (see ClinicalTrials.gov identiﬁer: NCT01942889)
investigated the effect of combined antioxidant (vitamins C and E,
selenomethionine, and zinc gluconate) with pulmonary rehabilitation
therapy to determine if dietary antioxidants could enhance the physio-
logical effects of exercise training; however, the results are not yet
published.
Reseveratrol, a polyphenol found most commonly in red wine, was
able to reduce some markers of oxidative stress in mouse models of
sarcopenia and disuse atrophy (Jackson et al., 2010, 2011). Resveratrol
treatment was not able to attenuate sarcopenia in ageing mice
(Jackson et al., 2011); however, it did reduce disuse atrophy in a
hindlimb suspension model (Jackson et al., 2010) and has recently
shown some promising effects in preventing cancer cachexia in the
mouse C26 colon cancer cachexia model (Shadfar et al., 2011). Current-
ly, there are no published data on the effect of resveratrol on muscle
mass in COPD; however, a trial is currently underway (see
ClinicalTrials.gov identiﬁer: NCT02245932) investigating the effects of
resveratrol in COPD patients and includes muscle volume and body
composition as secondary outcomes, so further information on resvera-
trol as a therapeutic option formusclewasting in COPDmaybe available
in coming years.
5.2. Strategies to increase glutathione levels
Glutathione is the most abundant non-protein thiol in muscle cells
and is a strong determinant of the intracellular redox status (Schafer &
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of the amino acid cysteine and acts as a strong reducing agent (Rahman
& Kinnula, 2012) that can act directly with ROS and RNS as well as
supporting glutathione synthesis through acting as a cysteine donor.
Initial results of trials in the use of NAC were mixed (Rahman &
Kinnula, 2012); however, high doses of NAC have been shown to be ef-
fective in reducingmucus hypersecretion and the frequency of acute ex-
acerbations of COPD, and NAC treatment is now included in the
American College of Chest Physicians and the Canadian Thoracic Society
guidelines for preventing acute exacerbations of COPD (Criner et al.,
2015). It is also included in the recent COPD-X guidelines in Australia
and New Zealand (Abramson et al., 2015).
Increasing levels of glutathione through the administration of gluta-
thione itself or NAC and other thiol donors improves measures of mus-
cle fatigue and reduces oxidative stress both in animal models and in
humans (Lands et al., 1999; Ferreira & Reid, 2008), including in COPD
patients (Koechlin et al., 2004).
Recently, a novel glutathione precursor, named FT061452 or F1, has
shown some efﬁcacy in reducing muscle loss in ageing mice (Sinha-
Hikim et al., 2013). Treatment with F1 resulted in reduced lipid peroxi-
dation, improved GSH/GSSG ratio, reduced IL-6, and increased phos-
phorylation of Akt suggesting increased protein synthesis signaling
through the Akt/mTOR pathway (Sinha-Hikim et al., 2013). Data on
this formulation are only available from preclinical animal models at
this time, and to date, no clinical studies have been conducted.
5.3. Nox inhibitors
Preclinical studies using antioxidants in cigarette smoke-exposed
mousemodels have shown that the nox2 inhibitor apocynin is effective
in reducing lung inﬂammation in inﬂuenza A-infected smoke-exposed
mice (Vlahos et al., 2011; Oostwoud et al., 2016). Apocynin reduces
the levels of hydrogen peroxide and nitric oxide in exhaled breath con-
densate of asthmatic patients (Stefanska et al., 2012), suggesting thera-
peutic potential for apocynin in the treatment of lung pathology in
COPD patients. Daily administration of apocynin in a mouse model of
chronic cigarette smoke exposure (8 weeks) resulted in improvements
in both lung inﬂammation andmusclemass (Vlahos, R. unpublished ob-
servations), offering promise that the therapeutic targeting of oxidative
enzymes could be a useful therapy for COPD and muscle wasting.
Whether these ﬁndings will translate into clinical beneﬁt in COPD pa-
tients warrants further investigation.
5.4. Antioxidant enzyme mimetics
Drugs thatmimic the effect of endogenous antioxidant enzymes have
been developedwith the aim of raising the levels of antioxidant defenses
and reducing oxidant burden. SOD mimetics can be classiﬁed into three
major classes—macrocyclic ligands, manganese metalloporphyrins, and
‘salens’ (manganese-based SOD mimetics) (Rahman & Kinnula, 2012).
While SOD mimetics have shown some promise in animal models of
lung inﬂammation (Rahman & Kinnula, 2012), they have not yet been
clinically tested for efﬁcacy in COPD or muscle wasting contexts.
Glutathione peroxidases are selenium-dependent antioxidant en-
zymes that catalyze the breakdown of reactive hydrogen peroxide to
water and oxygen (Vlahos & Bozinovski, 2013). Levels of systemic Gpx
have been shown to be depleted in COPD patients (Santos et al., 2004;
Vibhuti et al., 2007). The Gpx mimetic ebselen reduces lung inﬂamma-
tion in response to cigarette smoke (Duong et al., 2010) and inﬂuenza
infection (Yatmaz et al., 2013; Oostwoud et al., 2016) in mouse models,
suggesting that increasing the levels of Gpx activity could be a potential
therapeutic for COPD. The effects of Gpxmimetics on skeletalmuscle are
notwell characterized, particularly in the context of COPD. To the best of
our knowledge, no clinical trials have yet been reported for the use of
ebselen to treatmusclewasting in COPD, cancer cachexia, or sarcopenia.5.5. Nrf2 activators
The expression of many antioxidant enzymes, including Gpx, is reg-
ulated by signaling through the transcription factor Nrf2 (Rahman &
Kinnula, 2012). Disruption of Nrf2 in skeletal muscle impacts onmuscle
cell differentiation and regeneration and increasing the activity of Nrf2
by administration of sulforaphane has shown some efﬁcacy in mouse
muscular dystrophy models (Sun et al., 2015, 2016). However, there
are no published data on the expression and activity of Nrf2 in themus-
cles of COPD patients, and further investigation is warranted to fully
characterize the antioxidant defenses and redox balance at themolecu-
lar level in muscle from COPD patients and preclinical COPD models.
There are currently few therapeutic options to target oxidative stress
in muscle wasting (Table 2), and the full effect of reducing the oxidant
burden in COPD is not completely understood. Given the evidence of
elevated oxidative burden and oxidative damage in lungs, systemic cir-
culation and muscles of COPD and the known effects of oxidative dam-
age on tissue function, further investigation into the area is important.
(See Table 1.)
6. Inhibition of myostatin
The transforming growth factor (TGF)-β family member myostatin
has been identiﬁed as a key negative regulator of muscle mass
(McPherron et al., 1997), acting via both upregulation of atrophy
genes and inhibition of Akt signaling to promote proteolysis and reduce
protein synthesis. Deletion or mutation of the myostatin protein results
in dramatically increased muscle growth in mice (McPherron et al.,
1997), cattle (Grobet et al., 1997; McPherron & Lee, 1997), and humans
(Schuelke et al., 2004). Myostatin is also known to have other effects on
muscle physiology, including regulatingmuscle ROSproduction (Sriram
et al., 2011) and also ﬁber type (Girgenrath et al., 2005).
Myostatin signals through the activin receptor type IIB (ActRIIB), a
receptor that is sharedwith other TGF-β familymember proteins activin
and GDF11, which leads to phosphorylation of the transcription factors
Smad2/3. Signaling through the Smads 2/3 pathway regulates muscle
balance through inhibition of Akt and consequent activation of FOXO
transcription factors leading to upregulated expression of atrogenes,
and through direct effects of Smad on gene expression. In addition, it
is becoming increasingly recognized that the Smad pathway has exten-
sive cross-talk with other signaling pathways such as the mitogen-
activated protein kinase pathway, inducing other cellular effects that
regulate muscle atrophy and hypertrophy.
Consistent with its role in regulating muscle mass, myostatin ex-
pression is elevated in the vastus lateralis muscle from COPD patients
compared to healthy controls (Man et al., 2010; Plant et al., 2010). Cir-
culatingmyostatin protein is also elevated in serum fromCOPD patients
and correlates with reduced muscle mass in male COPD patients (Ju &
Chen, 2012).
A number of molecules targeting the myostatin/ActRIIB pathway
have been, or are currently being, tested for efﬁcacy in muscle wasting,
in both COPD and other cachectic conditions (Table 3). Given the dra-
matic effects on muscle mass arising from myostatin deletion or loss
of function, inhibition of myostatin itself using neutralizing antibodies
is an obvious therapeutic approach. This notion is supported by a num-
ber of in vivo studies that have used antibodies directed against
myostatin to treatmuscle wasting inmousemodels of cancer, disuse at-
rophy, sarcopenia, and glucocorticoid-induced wasting (Siriett et al.,
2007; Murphy et al., 2010, 2011; Latres et al., 2015; Smith et al., 2015).
Preclinical studies using the monoclonal antimyostatin antibody
LSN2478185 in naïve mice demonstrated an increase in muscle mass
(Smith et al., 2015). Testing of the humanized derivative of this anti-
body, LY2495655, in the mouse C26 tumor model and the PC3 tumor
model also demonstrated increased muscle mass and improvements
in grip strength compared to the isotype control antibody (Smith
et al., 2015). Interestingly, these antibodies also caused an increase in
Table 2
Therapeutic agents targeting myostatin and anabolic pathways to improve muscle wasting in COPD.
Drug name Mode of action Application Results Reference
Myostatin pathway inhibitors
Bimigrumab (BYM338) Activin II Receptor Antagonist Sarcopenia (NCT01669174) In progress NCT01669174
COPD (NCT01601600) In progress NCT01601600
LY2495655 Myostatin monoclonal
antibody
sarcopenia/frailty, hip replacement Improved muscle mass, reduced fat mass,
some improvement in physical performance
Becker et al., 2015;
Woodhouse et al., 2016
Pancreatic cancer cachexia In progress NCT01505530
REGN-1033 (Regeneron) Myostatin monoclonal
antibody
Healthy volunteers (NCT01910220)
Sarcopenia (NCT01963598)
In progress NCT01910220
NCT01963598
AMG-745 (Amgen) Peptibody (Fc-fusion protein) Cancer Increased muscle mass, reduced fat mass,
no improvement in physical performance
Padhi et al., 2014
Androgen receptor modulators
Enobosarm/Ostarine SARM Ageing/sarcopenia Increased lean body mass, decreased fat mass,i
mproved physical function (12 stair climb)
Dalton et al., 2011
Cancer cachexia Increased lean body mass, reduced fat mass
Improved 12 stair climb and power, no
improvement in 6MWD or hand grip strength
Dobs et al., 2013
Ghrelin/GH/IGF-axis
Ghrelin Stimulates GH secretion,
orexigenic
COPD Increase bodyweight and lean body mass
Increased muscle strength and 6MWD
Miki et al., 2012;
Nagaya et al., 2005
Anamorelin Ghrelin receptor agonist Cancer cachexia Increased lean body mass Garcia et al., 2015
Cancer cachexia
(non-small-cell lung cancer)
Increased lean body mass.
No increase in handgrip strength
Temel et al., 2016
Cancer cachexia
(non-small-cell lung cancer)
Increased lean body mass, QOL and KPS scores.
Increased IGF-1 levels
No change in handgrip strength
Takayama et al., 2016
SUN11031 Synthetic Ghrelin COPD Increased bodyweight and lean body mass,
increased serum IGF-1, no overall improvement in
6MWD or handgrip strength, although some
improvement in subset of severe COPD patients.
Levinson & Gertner, 2012
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be of importance in the treatment ofmusclewasting in patientswith re-
duced appetite and calorie intake as is often the case in COPD.
Thehumanized antimyostatin antibody LY2495655 (Landogrozumab)
has since progressed to clinical trials and has demonstrated someprom-
ising, if modest, effects on muscle size in humans. In elderly patients
with a history of falls, LY2495655 treatment resulted in a 2.5% increase
in appendicular lean body mass after 24 weeks and showed aTable 3
Studies investigating the efﬁcacy of neuromuscular electrical stimulation for treating muscle w
Study population Training protocol Effects o
After AECOPD (hospitalized) 35 Hz, 1 h per day, 5 days/week for 6 weeks.
Both legs, hamstrings and quads.
Increase
(and red
ﬁber typ
During AECOPD 50 Hz, 30 min, 1× per day for 14 days.
One leg only, quads and vastus medialis.
Increase
(untrea
COPD 50 Hz, 30 min daily for 6 weeks.
Both legs, quads only.
Increase
Increase
COPD (moderate to severe,
FEV1 b 50% predicted)
50 Hz, 30 min per day, 5 days per week for
6 weeks. Both legs.
Increase
(decrea
Reduced
COPD (severe to very severe,
FEV1 b 35% predicted)
HF-NMES (75 Hz) or LF-NMES (15 Hz),
18 min 2× per day, 5 days per week
for 8 weeks.
Increase
Increase
but grea
Reduced
COPD (moderate to severe
FEV1 b 40% predicted)
50 Hz, 60 min, 2× per day, 5 days per
week for 8 weeks. Both legs, quads.
Increase
Increase
Increase
Reduced
COPD (severe) 50 Hz, 35 min quads, 25 min calves,
5× per week for 6 weeks. Both legs.
Increase
and 6M
Downre
anabolic
COPD (moderate to severe,
FEV1 b 60% predicted,
except 1 patient)
50 Hz, up to 1 h/eg, 5× per week for
6 weeks. Both legs, quads.
No sign
and 6M
Signiﬁca
ﬁber CS
Abbreviations: MVC, maximal voluntary contraction; 6MWD, 6 minute walk distance; CSA, crocorresponding increase in total lean body mass and a reduction in fat
mass (Becker et al., 2015). Treatment with LY2495655 also resulted in
general increases in physical performance in tests of fast gait speed,
stair climbing, and chair rising, although improvements in hand grip
strength were not signiﬁcant and no improvement was seen in isomet-
ric leg extension. Clinical trials for the use of LY2495655 to treat muscle
atrophy in patients undergoing a total hip arthroplasty have revealed
some efﬁcacy in increasing muscle mass at 105 and 315 mg; however,asting in COPD.
f NMES Reference
d MVC and 6MWD, reduced muscle protein carbonylation
uced myosin heavy chain carbonylation);
e shift (increased Type I, decreased Type IIx).
Abdellaoui et al., 2011
d quadriceps MVC in NMES treated leg
ted leg decreased MVC)
Giavedoni et al., 2012
d 6MWD and MVC in NMES group vs placebo.
d quad CSA.
Maddocks et al., 2016
d quad strength (peak torque)and endurance
sed fatigue).
dyspnea.
Neder et al., 2002
d quad peak torque after HF-NMES but not LF-NMES.
d endurance (total work) in HF-NMES and LF-NMES,
ter increase with HF-NMES.
dyspnea.
Sillen et al., 2014
d FEV1 and exercise tolerance, reduced dyspnea.
d 6 MWD.
d fat-free mass, muscle mass and thigh CSA.
TNFα and increase β-endorphin levels.
Vieira et al., 2014
d mid-thigh and calf muscle CSA, improved strength
WD (apart from 6 non-responder patients).
gulation of catabolic protein atrogin-1, increase in
pathway protein p70S6K.
Vivodtzev et al., 2012
iﬁcant effect of NMES on leg muscle mass, peak torque
WD.
nt increase in Type II ﬁber CSA and a decrease in Type I
A—no changes in relative proportion of ﬁber types.
Dal Corso et al., 2007
ss-sectional area; HF-NMES, high-frequency NMES; LF-NMES, low-frequency NMES.
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(Woodhouse et al., 2016). The antibody has also been tested for use in
cancer cachexia in patients with pancreatic cancer (see ClinicalTrials.
gov identiﬁer: NCT01505530), although results are not yet available
on the outcome of this trial.
REGN1033 is a fully humanized, antimyostatinmonoclonal antibody
developed by Regeneron, that shows high speciﬁcity for binding
myostatin and no detectable binding of either GDF11 or activin (Latres
et al., 2015). In vitro reporter gene assays conﬁrmed that the antibody
speciﬁcally blocks Smad phosphorylation and activation following
myostatin treatment but not after treatment with activin, further
conﬁrming the speciﬁcity of the antibody against myostatin alone. In
naïve mice, REGN1033 caused a signiﬁcant 19–25% increase in the
weight of the gasctrocnemius following 28 days of treatment, with a
similar magnitude effect in the tibialis anterior. The increased muscle
size was accompanied by an increase in the isometric force production
of the tibialis anterior, with maximal tetanic force increasing by 16.7%,
indicating that muscle functional performance is also improved follow-
ing treatment. In models of disuse atrophy and glucocorticoid-induced
atrophy, REGN1033 prevented loss of both muscle mass and function.
Following these promising preclinical results, REGN1033 is now in
clinical testing. Initial clinical trials have been completed for safety and
bioeffect (see ClinicalTrials.gov identiﬁer: NCT01910220) and more
recently for safety and efﬁcacy in patients with sarcopenia (see
ClinicalTrials.gov identiﬁer: NCT01963598).
A slightly different approach to inhibition of myostatin has been de-
veloped in the form of AMG-745, a peptibody against myostatin.
Peptibodies are fusion proteins consisting of an active peptide fused to
the Fc portion of an antibody and offer a number of advantages over in-
dividual peptides and antibodies as therapeutic agents, including im-
proved longevity in vivo (Shimamoto et al., 2012). AMG-745 contains
a fusion protein with a human Fc at the N-terminus, and a C-terminal
bioactive peptide that neutralizes myostatin activity (Padhi et al.,
2014). Initial clinical trials have shown results similar to those seen
withmonoclonal antibodies; in patients receiving androgendeprivation
therapy for prostate cancer, AMG-745 treatment resulted in a 2.2% in-
crease in lean body mass compared to placebo, and an overall decrease
in fatmass of around 2.5% at 1month follow up after a 28 day treatment
protocol (Padhi et al., 2014). Similar to the ﬁndings with LY2495655, no
improvement in leg strength was seen following AMG-745 treatment,
suggesting either that a greater level of myostatin inhibition is needed
or that inhibitingmyostatin alone is not sufﬁcient to translate into func-
tional improvement.
In addition to myostatin, other TGF-β family members such as
activin also exert effects onmusclemass via ActRIIB suggesting a certain
level of redundancy within this pathway that requires important con-
sideration for the development of therapeutics targeting myostatin
and its signaling pathway.
An alternative strategy to inhibiting or neutralizing myostatin itself
is to develop receptor antagonists that prevent myostatin from binding
to ActRIIB and initiating downstream signaling. This strategy has
worked well in cell culture and mouse models, where the ActRIIB anti-
body Bimagrumab (BYM338) effectively prevented the atrophic effects
of myostatin and activin on cultured myotubes and caused muscle hy-
pertrophy in mice (Lach-Triﬁlieff et al., 2014). Bimagrumab also
inhibited the muscle wasting in response to glucocorticoid treatment
in mice, a ﬁnding that may be of particular interest in the context of
COPD where many patients are treated with glucocorticoids that are
known to negatively impact on muscle mass and health. Interestingly,
Bimagrumab also increased muscle mass in a mouse carrying a loss of
function mutation in the myostatin gene, suggesting additional ligands
such as activin play important roles in the regulation of muscle mass.
ActRIIB blockade with Bimagrumab was around twice as effective as
treatment with the myostatin-speciﬁc inhibitor propeptide D76A, fur-
ther emphasizing the overlap in function between different TGF-β fam-
ily members. This indicates that blockade at the point of receptorsignaling is likely a more effective strategy than targeting ActRIIB li-
gands individually.
Together theseﬁndings provide ample support for further testing into
possible clinical uses of Bimagrumab in muscle wasting conditions. In-
deed clinical trials have recently been completed to test the efﬁcacy of
Bimagrumab in both sarcopenia (see ClinicalTrials.gov identiﬁer:
NCT01669174) and muscle wasting in COPD patients (see ClinicalTrials.
gov identiﬁer: NCT01601600), results have not yet been made available.
7. Anabolic therapies
Body composition in COPD patients is complex, and loss of muscle
mass can occur with or without accompanying changes in fat mass,
resulting in a population of patients with underlying muscle dysfunc-
tion but varying levels of underweight or obesity (Schols et al., 2005;
Steuten et al., 2006). While higher body weight is generally associated
with a better prognosis for COPD patients, excess body fat and obesity
are associated with additional health risks. Anabolic therapies are
aimed at increasingmusclemass through stimulation of protein synthe-
sis and reduction of protein breakdown, while preferably avoiding ex-
cess fat gain, so promoting a favorable body composition to improve
overall health.
7.1. Insulin-like growth factor-1
IGF-1 appears to be an attractive therapeutic target due to its posi-
tive effects on muscle hypertrophy; however, previous trials adminis-
tering recombinant human IGF-1 have yielded mixed results in human
patients with a range of muscle conditions including sarcopenia and
cancer cachexia (Philippou & Barton, 2014). The biology of IGF-1 is
complex—there are several isoforms of the protein and the protein is
subject to post-translational processing—and several issues make ther-
apeutic administration of IGF-1 problematic. The IGF-1 receptor is ubiq-
uitously expressed and IGF-1 is a potent growth factor affecting cell
proliferation and survival in many tissues, therefore IGF-1 administra-
tion could represent an increased cancer risk; a concern that has limited
the doses and timeframes of IGF-1 administration in clinical trials to
date (Philippou & Barton, 2014).
Therapeutic methods aimed at increasing the local expression of
IGF-1 within the muscle tissue may be more effective in promoting
muscle hypertrophy and may help to avoid unwanted systemic effects.
Gene transfer or virus-mediated expression of IGF-1 within muscle tis-
sue has been shown to be effective in increasing IGF-1 and promoting
muscle repair and growth in animal models (Barton-Davis et al., 1998;
Schertzer & Lynch, 2006) but has yet to be transferred to human studies.
Although there are currently some trials investigating theuse of IGF-1 in
the treatment of muscular dystrophy, at present, to the best of our
knowledge, no trials are in progress for the use of IGF-1 to treat muscle
wasting in COPD.
A number of other anabolic hormones have been tested for efﬁcacy
in COPD patients, including testosterone, ghrelin, and growth hormone
analogues and offer promise for future therapeutic use.
7.2. Testosterone
Perhaps the most widely known anabolic compound is the anabolic
hormone testosterone, which has potent anabolic activity in muscle
cells along with a lipolytic effect resulting in increased muscle mass
and reduced fat mass (Dubois et al., 2012). Testosterone signals both
through the androgen receptor and also via crosstalk with a number
of intracellular signalingpathways to regulate protein synthesis and sat-
ellite cell differentiation, leading to an increase in muscle mass (Dubois
et al., 2012).
Testosterone administration is known to increase the size of muscle
ﬁbers in a similar manner to that seen with resistance training. Testos-
terone itself must be administered by injection, or through the skin
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been developed that can be taken orally. Testosterone analogues have
shown some promising results in COPD, with patients in a number of
clinical studies showing increases in muscle mass following treatment
(Schols et al., 1995; Creutzberg et al., 2003; Casaburi et al., 2004). To
date, however, these changes have not consistently translated into
other measurable patient-centered outcomes such as exercise capacity
and lung function (Velema et al., 2012; Pan et al., 2014b).
Testosterone exerts both anabolic and androgenic effects, and the
administration of testosterone and its analogues is associated with a
number of side effects, including increased risk of cardiovascular events
and dermatological disorders (Basaria et al., 2010), that have limited its
uptake in clinical practice. In recent years, a new class of molecules
known as selective androgen receptor modulators (SARMs) have been
developed that interact with the androgen receptor and can mimic
some of the effects of testosterone while avoiding some of the side ef-
fects (Mohler et al., 2009). These molecules offer some promise for the
therapeutic treatment of muscle wasting in COPD and have recently
been tested in clinical trials (See Table 2).
The nonsteroidal SARM Enobosarm (GTx-024) is reported to in-
crease muscle mass and bone density in animal models and in healthy
human males (Dalton et al., 2011). In elderly men and postmenopausal
women, Enobosarm at 3 mg per day for 86 days caused a signiﬁcant
1.3 kg increase in lean body mass, which was accompanied by a signif-
icant decrease in fat mass (Dalton et al., 2011). This increase also ap-
peared to translate into improved function, with patients showing a
decrease in the time to climb 12 stairs and an increase in stair climb
power (Dalton et al., 2011). Amore recent trial investigating the efﬁcacy
of Enobosarm in cancer patients also demonstrated a signiﬁcant im-
provement in lean body mass and reduced fat mass (Dobs et al.,
2013). No signiﬁcant improvement was seen in 6-minute walk test or
hand grip strength; however, Enobosarm-treated patients showed a de-
crease in stair climb time and increased stair climb power compared to
placebo-treated patients, suggesting some improvement in muscle
function following Enobosarm treatment (Dobs et al., 2013).
At this time, no trials are currently registered for the investigation of
the effectiveness of SARMs in treating muscle wasting underlying
COPD; however, this avenue offers promise, particularly in combination
with other therapeutic approaches such as the combination of nutri-
tional intervention and exercise training, which has been demonstrated
to be an effective multimodal treatment approach in previous studies
(Casaburi et al., 2004).
7.3. Ghrelin
Ghrelin is a peptide hormone of 28 amino acids that regulates
growth hormone (GH) secretion from the anterior pituitary gland and
has a number of effects with potential beneﬁt for treating muscle
wasting in COPD. Ghrelin is a potent orexigenic agent, stimulating appe-
tite and feeding (Wren et al., 2001a, 2001b). Such effects could be ben-
eﬁcial in COPD patients who have reduced appetite and calorie intake.
In addition, ghrelin can indirectly stimulate protein synthesis through
stimulation of the GH-IGF-1 axis, promotingmuscle anabolic processes.
It also stimulates adiposity through inhibition of fat oxidation (Tschop
et al., 2000), implying that caution may be needed in administering
ghrelin to patients with higher fat mass.
Ghrelin levels appear to be higher in underweight patients with
COPD compared to healthy controls (Itoh et al., 2004; Uzum et al.,
2014) and normal weight COPD patients (Itoh et al., 2004), a phenom-
enon that has been observed in other cachectic states (Nagaya et al.,
2001; Shimizu et al., 2003). Another study found reduced ghrelin levels
in COPD patients (mean BMI of 18.5) compared to healthy controls
(mean BMI 22) (Luo et al., 2005). The reason behind this discrepancy
is unclear but may reﬂect differences in the COPD populations sampled
(e.g., current smoking status, different inclusion criteria) and methodo-
logical differences in the isoforms of ghrelin measured in each study.Clinical studies administering human ghrelin to COPD patients re-
sulted in increased bodyweight and lean body mass and increases in
both limb and respiratory muscle strength (Nagaya et al., 2005). Func-
tional improvements have also been reported following ghrelin admin-
istration, with improved 6-minute walk distance reported in two
studies (Nagaya et al., 2005; Miki et al., 2012). A recent study using
the synthetic ghrelin peptide SUN11031 similarly resulted in increased
bodyweight and lean body mass, accompanied by increased levels of
IGF-1 (Levinson & Gertner, 2012). This study did not observe signiﬁcant
increases in 6-minute walk distance or handgrip strength in the overall
trial population following SUN11031 treatment. However, in a post-hoc
analysis of a subpopulation of patientswith advancedmusclewasting at
baseline then treated with the highest dose of SUN11031 had a signiﬁ-
cant increase in 6MWD and handgrip strength compared to placebo-
treated patients.
The ghrelin receptor agonist anamorelin has not yet been tested in
the context of COPD-associated muscle wasting. It has shown positive
results on lean body mass in clinical studies in cancer cachexia; howev-
er, no increase in handgrip strength was observed despite increases in
IGF-1 (Garcia et al., 2015; Takayama et al., 2016; Temel et al., 2016).
Despite evidence of increased bodyweight and lean body mass fol-
lowing treatment targeting the ghrelin pathway in cachectic patients
with both COPD and other conditions, the translation of increased
mass to improvements in strength and physical function has not been
consistently demonstrated. Despite this, therapies targeting the
ghrelin-GH pathway may still hold promise and, in combination with
effective pulmonary rehabilitation programs, could result in beneﬁcial
increases in both muscle mass and function (See Table 2).
8. Physical inactivity and pulmonary rehabilitation
Numerous studies have shown that COPDpatients are less physically
active than healthy controls (Watz et al., 2009; Troosters et al., 2010;
Vorrink et al., 2011; Watz et al., 2014), and physical inactivity is seen
as a major contributor to the muscle wasting and loss of strength seen
in COPD patients.
As with healthy people, physical activity and exercise have numer-
ous health beneﬁts in patients with COPD and exercise training through
pulmonary rehabilitation programs is currently the gold standard for
improving muscle strength and function (Spruit et al., 2013). Pulmo-
nary rehabilitation incorporates a range of interventions including edu-
cation, behavioral change, and exercise training with the aim of
improving the physical and psychological condition of people with
COPD (Spruit et al., 2013). The beneﬁcial effects of exercise training in
pulmonary rehabilitation are well established and a recent systematic
review of 65 randomized controlled trials revealed that pulmonary re-
habilitation leads to improvements in exercise capacity as well as in
quality of life scores including symptoms of fatigue and dyspnea
(McCarthy et al., 2015).
COPD patients often exhibit exercise intolerance due to a variety of
factors including dyspnea, ventilatory limitation, fatigue, and peripheral
muscle dysfunction (Spruit et al., 2013). Although exercise training in
COPD patients is an effective therapeutic approach, the training modal-
ities of pulmonary rehabilitation programs vary and there is still some
debate about the most effective training protocols for the heteroge-
neous COPD population and a need to develop tailored training pro-
grams to accommodate differing patient abilities and needs.
Commonly used training modes include endurance/aerobic training
and resistance/strength training, and protocols and training programs
often differ evenwithin individual trainingmodalities. Endurance train-
ing, commonly through stationary cycling or walking activities, aims to
condition the ambulatory muscles and improve cardiovascular ﬁtness
(Spruit et al., 2013). Factors such as duration, frequency, and intensity
are important determinants of the physiological adaptations to exercise
training. Although the optimal duration for a pulmonary rehabilitation
is unclear, evidence of beneﬁt in exercise capacity and quality of life is
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or 3 day per week 6–12 week program (Bolton et al., 2013). In addition
to the supervised exercise, patients are encouraged to continue exercis-
ing at home during the period of the program, following standard exer-
cise prescription guidelines such as those of the American College of
Sports Medicine, with exercise sessions of 20–60 min, 3–5 times per
week at N60% of the patient's maximal work rate (Garber et al., 2011).
Endurance training leads to improved exercise capacity (Whittom
et al., 1998; Troosters et al., 2000; Ortega et al., 2002; Vogiatzis et al.,
2007, 2011). Additional increases in muscle cross-sectional area, IGF-1
expression, and a shift toward more oxidative type I ﬁbers have also
been reported (Vogiatzis et al., 2007, 2011).
Resistance or strength training involves lifting heavy weights for a
prescribed number of repetitions, to build strength and increase muscle
mass in individual muscles or muscle groups through upregulation of
the mTOR signaling pathway (Terzis et al., 2008; Walker et al., 2011).
Numerous randomized controlled trials have conﬁrmed that resistance
training protocols increase arm and leg strength, exercise capacity and
muscle mass in COPD patients (O'Shea et al., 2009; Vonbank et al.,
2012; Constantin et al., 2013). Similar changes in muscle size and iso-
metric strength were observed in healthy controls and COPD patients
after an 8 week resistance protocol, conﬁrming that the muscles of
COPD patients are still able to respond to strength training stimuli to
the same extent as healthy controls, despite starting from a depleted
baseline (Constantin et al., 2013).
While resistance training is well accepted as amethod for improving
strength, its effects on aerobic ﬁtness and exercise endurance are less
apparent. Resistance training results in some improvement in walking
distance and cycling endurance compared to no exercise; however, it
ismuch less effective than endurance/aerobic training at improvingper-
formance in these areas (O'Shea et al., 2009). It is likely that a combined
training program including both resistance and endurance exercisemo-
dalities would be optimal to increasemusclemass, strength, and endur-
ance in COPD patients, a hypothesis that has been supported by several
studies (Ortega et al., 2002; Vonbank et al., 2012; Zambom-Ferraresi
et al., 2015), and indeed most pulmonary rehabilitation programs in-
clude aspects of both endurance and resistance exercise to maximize
gains from both modalities.
Despite the accepted beneﬁts of exercise training for improving
muscle mass and function in COPD patients, a number of therapeutic
challenges still remain. Within the COPD population, there are ‘non-re-
sponder’ patients who do not show improvement with exercise inter-
ventions, largely due to the presence of more severe airﬂow limitation
or comorbidities (Hill & Holland, 2014). It is estimated that around
50% of patients referred for pulmonary rehabilitation present with
comorbidities that affect their ability to exercise, the most common
of which are metabolic disorders (hypertension, diabetes, and
dyslipidaemia) and heart diseases (chronic heart failure and coronary
heart disease) (Crisafulli et al., 2008). Patients with comorbidities
were still able to respond to exercise training and improve their physical
capacity (Crisafulli et al., 2008); however, tailored and multimodal
training programs are needed to accommodate the needs and abilities
of different COPD patients, and a number of additional interventions
have been proposed (Hill & Holland, 2014).
8.1. Interval training
Interval training involves performing short periods of intense exer-
cise interspersed with periods of rest or lower intensity exercise. Al-
though used for years in the training of athletes, interval training has
emerged as an option for patient rehabilitation only recently. Interval
training is generally well tolerated and offers some beneﬁts for those
patients who are unable to tolerate long periods of continuous aerobic
exercise or are unable to achieve the target exercise intensity or dura-
tion to provide a sufﬁcient training stimulus for improvement (Spruit
et al., 2013). A number of trials have conﬁrmed the efﬁcacy of intervaltrainingmethods in COPD if the same total work is performed as an en-
durance protocol (Puhan et al., 2006; Beauchamp et al., 2010; Zainuldin
et al., 2011). Interval training is generally well tolerated and results in
lower symptom scores than continuous endurance exercise protocols,
despite similar overall work (Beauchamp et al., 2010).
8.2. Neuromuscular electrical stimulation
Neuromuscular electrical stimulation (NMES) involves external
electrical stimulation of isolated muscles via electrodes placed on the
skin to evoke an action potential within the muscle and cause involun-
tary contraction (Mafﬁuletti, 2010). NMES offers a number of advan-
tages for training of COPD patients; (1) the equipment used is
portable and easy to use, allowing patients to use the equipment in a
home setting for regular treatment; (2) NMES is generally well tolerat-
ed and has few side effects; (3) the exercise is passive, involving a low
ventilatory load, which may be useful for patients who are not able to
exercise due to respiratory symptoms; and (4) it can be used in
bedbound or even unconscious subjects, making it potentially useful
for maintaining muscle mass in hospitalized patients who cannot exer-
cise (Spruit et al., 2013).
Trials in the use of NMES have reported consistent beneﬁts in terms
of improvedmuscle size and function, exercise endurance and capacity,
improved lung function, and reduced dyspnea (Neder et al., 2002;
Abdellaoui et al., 2011; Giavedoni et al., 2012; Vivodtzev et al., 2012;
Sillen et al., 2014; Vieira et al., 2014; Maddocks et al., 2016)(see
Table 3). In a direct comparison of high-frequency NMES with a resis-
tance training protocol over 8 weeks, the increase in isokinetic quadri-
ceps strength was similar in the two training groups, indicating that
NMES can be as effective as traditional strength training (Sillen et al.,
2014) and supporting the notion that it may be a particularly useful
training modality to restore or maintain muscle mass in COPD patients
who have difﬁculty exercising, for example, during hospitalization for
an acute exacerbation (Zanotti et al., 2003; Vivodtzev et al., 2006).
In addition to improved muscle size and function, changes at the
level of muscle architecture and biochemistry have been reported fol-
lowing NMES in COPD patients, including decreased expression of the
atrophy-related gene atrogin-1 and increased phosphorylation (and
hence activity) of P70S6K, a protein involved in the anabolic protein
synthesis pathway (Vivodtzev et al., 2012). An increase in the propor-
tion of Type I and Type IIa/x ﬁbers has also been observed following
NMES, suggesting a fast-to-slow shift in ﬁber type toward amore oxida-
tive phenotype. Another study reported a decrease in Type I ﬁbers, albe-
it in a population with less severe COPD and with variations in the
stimulation protocol (Dal Corso et al., 2007). Other molecular changes
reported include a reduction inmarkers of oxidative stress in themuscle
of patients treatedwith NMES following acute exacerbation (Abdellaoui
et al., 2011), and a reduction in serum TNF-α levels (Vieira et al., 2014),
suggesting that NMES could affect levels of systemic oxidative stress
and inﬂammation in addition to its direct effects on muscle strength
and function.
While these observations are promising for the use of NMES to treat
muscle wasting in COPD, they must be interpreted with caution due to
the small size of many trials, the highly selected patients who were in-
cluded and wide variation in treatment protocols used (Sillen et al.,
2013; Pan et al., 2014a). Further investigation and large scale trials are
needed to fully optimize treatment protocols and evaluate efﬁcacy of
NMES for the treatment of muscle wasting in COPD, and indeed a num-
ber of such trials are either recently completed or currently recruiting pa-
tients (see ClinicalTrials.gov identiﬁers: NCT02321163, NCT01799330,
ISRCTN87439020, NCT02171377).
8.3. Muscle partitioning during exercise
Many COPD patients are not able to exercise at high intensity due to
ventilatory constraints, which may limit the extent to which muscular
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training. An alternative method is to partition or limit the exercise to a
smaller subset of muscle groups in order to reduce the ventilatory
load on the patient and allow them to exercise that muscle group at
higher intensity than they could if using larger muscle groups
(Richardson et al., 1999).
An example of this is one-legged cycling,which has emerged as a po-
tential training modality for COPD patients (Dolmage & Goldstein,
2006), and has been shown to improve peakmuscle power and oxygen
uptake while resulting in lower dyspnea than two-legged cycling at the
same workload (Dolmage & Goldstein, 2008; Bjorgen et al., 2009). To
date, only a few small trials have been conducted using this trainingmo-
dality in this area, and none have looked speciﬁcally at molecular or
phenotypic changes inmuscle tissue. Themethod is currently being ex-
panded in a trial using single and double leg elastic band exercises (see
ClinicalTrials.gov identiﬁer: NCT02283580), that includesmeasurement
of anabolic/catabolic signaling pathways, ﬁber types, and enzyme activ-
ities in the quadriceps muscles as secondary outcomes (Nyberg et al.,
2015). Partitioning exercise approaches remain a very promising thera-
peutic alternative to traditional exercise training and could be readily
translated into clinical practice (Evans et al., 2015).
8.4. Telehealth and community rehabilitation programs
Additional challenges in pulmonary rehabilitation include the prob-
lem of waning effects over the 12 months following completion of an
exercise training program, and improving access to enable patients
who have difﬁculty attending an outpatient rehabilitation program to
participate in structured and supervised exercise training and improve
their physical capabilities. It is estimated that up to 50% of patients
who are referred for pulmonary rehabilitation will never attend, and
dropout rates are estimated at 10–32% (Keating et al., 2011).
The relatively new and expanding ﬁeld of telehealth offers opportu-
nities for patients to participate in exercise programs in their own home
or within the community while still under the remote supervision of
trained medical staff and exercise therapists. Pilot studies using
telehealth approaches have shown some promise. Recent studies have
demonstrated improvements in 6MWD and dyspnea scores (Holland
et al., 2013a;Wang et al., 2014; Zanaboni et al., 2016); however, patient
numbers in each trial are still small. Ameta-analysis conducted on 9 tri-
als from 1996 to 2013 reported that telemedicine approaches did not
improve physical exercise capacity or dyspnea but may have an effect
on physical activity (Lundell et al., 2015); however, comparisons be-
tween trials were hampered by large variability in telehealth protocols
and outcome measures.
Home- or community-based telerehabilitation programs have been
shown to be well tolerated by participants, especially those living in re-
mote areas forwhom travelling to attend clinics is problematic (Burkow
et al., 2015). The cost of delivering such programs is variable depending
on the nature of the program and the equipment provided to partici-
pants but has been shown to be comparable or lower than the cost of at-
tending an outpatient clinic (Burkow et al., 2015). Current and
upcoming studies aimed at more directly comparing home-based pro-
grams with outpatient clinic rehabilitation will be valuable in address-
ing the direct and indirect costs associated with each mode of therapy
(see ClinicalTrials.gov identiﬁer: NCT01423227) (Holland et al., 2013b).
Some recent trials have further explored the use of modern technol-
ogy for the delivery of home-base rehabilitation, with some exciting re-
sults. Interesting studies from Wang and colleagues involved a home-
based walking program for COPD patients, which asked patients to
walk in time to the speed of music played on their mobile phones (Liu
et al., 2008; Wang et al., 2014). The tempo of the music was calculated
tomatch ameasuredwalking speed of 80% ofmaximalwalking capacity
based on exercise testing, allowing a fully personalized intervention to
encourage patients to exercise at the required intensity. Patients using
the music app showed clinically signiﬁcant increases in walkingdistance in the Incremental Shuttle Walk Test (ISWT) of 49 and 58 m
at 3 and 6 months, respectively, compared to baseline testing, which is
above the minimum important difference of 47.5 m (Singh et al.,
2008) and comparable to results typically seen following in-patient re-
habilitation programs (Spruit et al., 2013). Strength was also improved
after 6months in patients using themusic app,whereas control patients
given the same walking program but not using the app showed a de-
cline in walking distance over the same time period and no changes in
strength (Wang et al., 2014). Measures of inﬂammation (CRP, IL-8,
TNFα, and IL-6) all decreased in patients using the app compared to
controls (Wang et al., 2014).
9. Concluding remarks
In the last few decades, as skeletal muscle wasting has becomemore
recognized as a serious and prevalent comorbidity of COPD, our under-
standing of the molecular pathways leading to muscle wasting and the
complex interplay between the lung and systemic pathologies of COPD
has improved dramatically. As our knowledge ofmolecularmechanisms
leading tomusclewasting increases, so promising newpharmacological
targets are identiﬁed that could be targeted to reducemusclewasting or
delay disease progression.
Despite this, exercise training through pulmonary rehabilitation re-
mains the cornerstone of COPDmanagement with proven effectiveness
in improving lean body mass, physical capability, and lung symptoms.
Currently, there are no clinically proven licensed pharmacological ther-
apies for muscle wasting in COPD. While exercise training is effective,
many patients are limited in the amount and/or type of exercise they
can do or are not able to access pulmonary rehabilitation services.
There is a clinical need to develop effective pharmacological agents
and therapeutic approaches to target muscle wasting processes in
COPD, acting either alone or in conjunction with pulmonary rehabilita-
tion programs.
The mechanisms of wasting in COPD are complex, including contri-
butions from physical activity, systemic inﬂammation, lack of appetite,
hormone signaling, and oxidative stress. It is likely that wasting may
be worsened in patients for whommultiple factors are involved, for ex-
ample, those who show elevated systemic inﬂammation, lack of appe-
tite, and reduced physical activity. The signaling pathways leading to
wastingmay also interactwith each other, working synergistically to in-
crease atrophy. While it is unlikely that targeting a single aspect will be
an effective approach to treating such a complex condition, it may be
that even reducing the impact of a single factor could lead to clinically
meaningful improvements in muscle mass and strength. However, the
most promising outcome is likely to be achieved from combining
therapeutic approaches to tackle multiple factors simultaneously.
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